262 related articles for article (PubMed ID: 23790097)
21. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer.
Reck M; Kaiser R; Eschbach C; Stefanic M; Love J; Gatzemeier U; Stopfer P; von Pawel J
Ann Oncol; 2011 Jun; 22(6):1374-1381. PubMed ID: 21212157
[TBL] [Abstract][Full Text] [Related]
22. Safety profile and tolerability of antiangiogenic agents in non-small-cell lung cancer.
Gadgeel SM
Clin Lung Cancer; 2012 Mar; 13(2):96-106. PubMed ID: 22056889
[TBL] [Abstract][Full Text] [Related]
23. Multitargeted receptor tyrosine kinase inhibition: an antiangiogenic strategy in non-small cell lung cancer.
Socinski MA
Cancer Treat Rev; 2011 Dec; 37(8):611-7. PubMed ID: 21641723
[TBL] [Abstract][Full Text] [Related]
24. The potential of antiangiogenic therapy in non-small cell lung cancer.
Giaccone G
Clin Cancer Res; 2007 Apr; 13(7):1961-70. PubMed ID: 17404076
[TBL] [Abstract][Full Text] [Related]
25. Sorafenib for lung cancer: is the "Battle" still open?
Bria E; Pilotto S; Tortora G
Expert Opin Investig Drugs; 2012 Oct; 21(10):1445-8. PubMed ID: 22799503
[TBL] [Abstract][Full Text] [Related]
26. New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
Manegold C
Clin Lung Cancer; 2008; 9 Suppl 3():S100-8. PubMed ID: 19419923
[TBL] [Abstract][Full Text] [Related]
27. Targeting tumor neovasculature in non-small-cell lung cancer.
Pallis AG; Syrigos KN
Crit Rev Oncol Hematol; 2013 May; 86(2):130-42. PubMed ID: 23159217
[TBL] [Abstract][Full Text] [Related]
28. The potential role of nintedanib in treating colorectal cancer.
Rossi A; Latiano TP; Parente P; Chiarazzo C; Limosani F; Di Maggio G; Maiello E
Expert Opin Pharmacother; 2017 Aug; 18(11):1153-1162. PubMed ID: 28649871
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of motesanib diphosphate in non-small-cell lung cancer.
Rijavec E; Genova C; Barletta G; Biello F; Dal Bello MG; Coco S; Truini A; Vanni I; Alama A; Boccardo F; Grossi F
Expert Opin Pharmacother; 2014 Aug; 15(12):1771-80. PubMed ID: 25032887
[TBL] [Abstract][Full Text] [Related]
30. Antiangiogenic therapy in nonsmall cell lung cancer.
Gutierrez M; Giaccone G
Curr Opin Oncol; 2008 Mar; 20(2):176-82. PubMed ID: 18300767
[TBL] [Abstract][Full Text] [Related]
31. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F
Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548
[TBL] [Abstract][Full Text] [Related]
32. [Anti-angiogenic factors in thoracic oncology: successes, failures and prospects].
Marco S; Tomasini P; Greillier L; Barlesi F
Rev Mal Respir; 2011 Dec; 28(10):1216-29. PubMed ID: 22152931
[TBL] [Abstract][Full Text] [Related]
33. Anti-Angiogenics: Their Value in Lung Cancer Therapy.
Janning M; Loges S
Oncol Res Treat; 2018; 41(4):172-180. PubMed ID: 29631257
[TBL] [Abstract][Full Text] [Related]
34. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Langer CJ; Natale RB
Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
[TBL] [Abstract][Full Text] [Related]
35. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
Grothey A; Ellis LM
Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
[TBL] [Abstract][Full Text] [Related]
36. Emerging angiogenesis inhibitors for non-small cell lung cancer.
Malapelle U; Rossi A
Expert Opin Emerg Drugs; 2019 Jun; 24(2):71-81. PubMed ID: 31092048
[No Abstract] [Full Text] [Related]
37. Antiangiogenic agents and chemotherapy in advanced non-small cell lung cancer: a clinical perspective.
Girard N
Expert Rev Anticancer Ther; 2013 Oct; 13(10):1193-206. PubMed ID: 24134421
[TBL] [Abstract][Full Text] [Related]
38. Targeting Neovasculature with Multitargeted Antiangiogenesis Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer.
Skouras VS; Maragkos C; Grapsa D; Syrigos KN
BioDrugs; 2016 Oct; 30(5):421-439. PubMed ID: 27670779
[TBL] [Abstract][Full Text] [Related]
39. Nintedanib for the treatment of patients with advanced non-small-cell lung cancer.
Reck M; Heigener D; Reinmuth N
Expert Rev Clin Pharmacol; 2014 Sep; 7(5):579-90. PubMed ID: 25119062
[TBL] [Abstract][Full Text] [Related]
40. Targeting multiple angiogenic pathways simultaneously: experience with nintedanib in non-small-cell lung cancer.
Durm G; Hanna N
Future Oncol; 2014 May; 10(7):1167-73. PubMed ID: 24947258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
